Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0549473
Disease: Thyroid carcinoma
Thyroid carcinoma
0.380 Biomarker disease BEFREE The mammalian target of rapamycin (mTOR) pathway is overactivated in thyroid cancer (TC). 29757257 2018
CUI: C0549473
Disease: Thyroid carcinoma
Thyroid carcinoma
0.380 AlteredExpression disease BEFREE ALA suppressed thyroid cancer cell proliferation through activation of AMPK and subsequent down-regulation of mammalian target of rapamycin (mTOR)-S6 signaling pathway. 26463583 2016
CUI: C0549473
Disease: Thyroid carcinoma
Thyroid carcinoma
0.380 Biomarker disease BEFREE Additionally, knockdown of TSC2, the upstream regulatory molecule of mTOR pathway, or treatment of rapamycin, the mTOR inhibitor, could abolish the effects of metformin to regulate thyroid cancer cell proliferation, migration, EMT, and mTOR pathway molecules. 25854169 2015
CUI: C0549473
Disease: Thyroid carcinoma
Thyroid carcinoma
0.380 AlteredExpression disease BEFREE Thyroid cancer cells lose TSH/cAMP dependency of mTOR signaling and cell growth. mTOR activity is not decreased by the MEK or AKT inhibitors in the RAS or BRAF human thyroid cancer cell lines. 25029414 2014
CUI: C0549473
Disease: Thyroid carcinoma
Thyroid carcinoma
0.380 Biomarker disease BEFREE These data establish mTOR as a key mediator of RET-mediated cell growth in thyroid cancer cells and provide a rationale for combinatorial treatments in thyroid cancers with oncogenic RET mutations. 23828865 2013
CUI: C0549473
Disease: Thyroid carcinoma
Thyroid carcinoma
0.380 GeneticVariation disease BEFREE Moreover, our results suggest that the mTOR pathway could be a good target to enhance therapy effects in certain types of thyroid carcinoma, namely in those harboring the BRAF(V600E) mutation. 22549934 2012
CUI: C0549473
Disease: Thyroid carcinoma
Thyroid carcinoma
0.380 Biomarker disease BEFREE MK2206 also completely overcame the feedback activation of Akt from temsirolimus-induced mammalian target of rapamycin suppression, and the two inhibitors synergistically inhibited thyroid cancer cell growth. 21289267 2011
CUI: C0549473
Disease: Thyroid carcinoma
Thyroid carcinoma
0.380 Biomarker disease BEFREE This genotype-based targeting of the PI3K/Akt pathway using Akt and mTOR inhibitors may offer an effective therapeutic strategy for thyroid cancer and warrants further studies. 19706758 2009
CUI: C0549473
Disease: Thyroid carcinoma
Thyroid carcinoma
0.380 CausalMutation disease CGI